Securities code: 600767 securities abbreviation: Winsan(Chengdu) Medical Science And Technology Company Limited(600767) Announcement No.: 2022-001 Yunsheng (Chengdu) Medical Technology Co., Ltd
Announcement on Retrial of litigation matters
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The litigation stage of the case: retrial stage
Party status of listed companies: the amount involved in the retrial of the respondent (defendant of first instance and appellant of second instance): 5.5 million yuan
Whether it will have a negative impact on the profits and losses of listed companies: given that the retrial has not been heard in court and the review results are uncertain, it is impossible to judge the impact on the company’s profits in the current period or after the period.
1、 Basic information of the retrial of this lawsuit
Recently, the people’s Court of Shanghai (hereinafter referred to as “Shanghai Yunsheng) Co., Ltd. has received the notice of civil retrial of the case issued by Chengdu Yunsheng Technology Co., Ltd. (hereinafter referred to as” Shanghai No. 2022 “). Jiang Shenying (plaintiff in the first instance and appellee in the second instance) refused to accept the civil judgment (2021) Hu 01 min Zhong No. 14059 made by Shanghai No. 1 Intermediate People’s court due to the dispute over guarantee contract, applied to Shanghai Higher People’s court for retrial, requested to revoke the civil judgment (2021) Hu 01 min Zhong No. 14059 and ruled to retrial the case according to law. At present, the Shanghai Higher People’s court has filed a case for examination.
2、 Background of this retrial
In August 2017, Jiang Shenying filed a lawsuit with Shanghai Pudong New Area People’s Court on the loan dispute with Zhongxin Huitong commercial factoring Co., Ltd. (hereinafter referred to as “Zhongxin Huitong”), and asked the company to bear joint and several repayment liabilities. In April 2019, the court made a final judgment that the guarantee was not effective for the company, and the company should not bear joint and several guarantee liability. (see announcement on litigation involving the company and its holding subsidiaries for details, Announcement No.: 2019-023)
On September 15, 2020, Jiang Shenying again filed a lawsuit with the people’s Court of Pudong New Area, Shanghai, asking the company to bear the compensation liability of RMB 5.5 million (including the principal of RMB 5 million and interest) after the guarantee contract is invalid
500000 yuan). In June 2021, the people’s Court of Pudong New Area of Shanghai issued a civil judgment (2020) Hu 0115 min Chu No. 81001, which ruled that the company should be liable for 40% of the unliquidated part of the debt that Zhongxin Huitong should repay Jiang Shenying’s loan of 5 million yuan and the debt that should pay Jiang Shenying’s loan interest of 500000 yuan. Since then, the company refused to accept the result of the first instance judgment, appealed to the Shanghai No. 1 Intermediate People’s court, and received the civil judgment (2021) Hu 01 min Zhong No. 14059 issued by the Shanghai No. 1 Intermediate People’s court in December 2021, which revoked the civil judgment (2020) Hu 0115 min Chu No. 81001 issued by the Shanghai Pudong New Area People’s court; Jiang Shenying’s claim was rejected. (for details, see announcement on litigation progress and announcement on litigation results, Announcement No.: 2021-039 and 2021-059)
3、 The impact of the retrial of this lawsuit on the company
In view of the fact that the retrial case has not been heard in court and the review results are uncertain, it is impossible to judge the impact on the company’s profits in the current period or after the period.
The company will actively respond to the lawsuit according to law, pay close attention to the progress of the retrial, and timely fulfill the obligation of information disclosure. Please pay attention to the investment risks.
It is hereby announced.
Board of directors of Yunsheng (Chengdu) Medical Technology Co., Ltd. January 7, 2022
